The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00564356

Enrollment

Registered

2007-11-27

Start date

2007-07-31

Completion date

2010-12-31

Last updated

2009-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy, Complications

Keywords

cataract, phacoemulsification, coumadin, antiaggregants

Brief summary

To assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification in patients on coumadin and antiaggregant treatments. Design: Consecutive prospective study.

Detailed description

To assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification technique in patients on coumadin and antiaggregant treatment Design: Consecutive prospective study.

Interventions

PROCEDUREcataract surgery with phacoemulsification

removal of cataract with phacoemulsification technique

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients who give informed consent to participate in the study

Exclusion criteria

* single eye complicated cataract

Design outcomes

Primary

Measure	Time frame
safety and efficacy of cataract surgery with phacoemulsification under coumadin and antiaggregant treatment	3.5 years

Secondary

Measure	Time frame
other complications	3.5 years

Countries

Israel

Contacts

Primary ContactOphira Salomon, MD

ophiras@sheba.health.gov.il972-3-5302104

Backup ContactYael Wasserzug, MD

yawlwasserzug@gmail.com972-3-5302874

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026